Compare Charles River Laboratories Intl. Inc (CRL) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Keysight Technologies Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.28 (market cap $11.14B), while Keysight Technologies Inc trades at $322.1 (market cap $55.67B). The key difference: Keysight Technologies Inc is far larger — about 5× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Keysight Technologies Inc nearer its low. Which is the better fit depends on your goals.
| CRL | KEYS | |
|---|---|---|
Market Cap | $11.14B | $55.67B |
Sector | Health | Technology |
52-Week High | $233.60 | $373.34 |
52-Week Low | $145.57 | $158.51 |
Enterprise Value | $14.00B | $56.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Keysight Technologies (KEYS) trades at $320.83, down 0.38% today, with technical indicators showing a bearish trend near key support at $317. The company reported strong Q1 2026 earnings of $2.87 per share, beating estimates of $2.32, and maintains robust profitability with a 17.31% net income margin. Recent news highlights product launches in network cybersecurity and photonics design, supporting growth in AI and 5G markets.
Wall Street maintains a bullish outlook with a $396.56 consensus price target and 75% buy ratings, though high valuation multiples and volatile cash flows pose risks. Upside potential hinges on execution in high-growth tech sectors, while investor sentiment is tempered by near-term technical weakness and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
